The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities ...

Katherine Szarama, who has served as Prasad’s deputy at the Center for Biologics Evaluation and Research since December, joins a long list of temporary leaders at the Department of Health and Human ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Eli Lilly’s $19.8 billion revenue for the first quarter could have been higher if not for declining prices for key medicines ...

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...

Members of the FDA’s Oncologic Drugs Advisory Committee questioned AstraZeneca’s trial design of switching treatments earlier ...

GENEVA-- (BUSINESS WIRE)--Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see ...

Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at ...

CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s ...

Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t ...

After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers ...

The patient death occurred outside the U.S. and was deemed unrelated to Newron Pharmaceuticals’ investigational schizophrenia ...